Agios Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Agios Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $40.25. The average 1-year stock price forecast is 36.63% higher than the current stock price, while the lowest is $28 (-4.96%) and the highest is $59 (+100.27%).

Price Target: $40.25 (+36.63%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$28	$40.25	$38	$59
Change	-4.96%	+36.63%	+28.99%	+100.27%

Analyst Ratings

The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	7	7	7	7
Buy	0	0	0	0	0	0
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	10	10	10	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $40	Buy	Maintains	$40	+35.78%	Jun 12, 2026
Tessa Romero J.P. Morgan	J.P. Morgan	Hold Reiterates $36 → $31	Hold	Reiterates	$36 → $31	+5.23%	Jun 10, 2026
Marc Frahm TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 2, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Hold Maintains $32	Hold	Maintains	$32	+8.62%	Jun 2, 2026
Emily Bodnar H.C. Wainwright	H.C. Wainwright	Buy Reiterates $50	Buy	Reiterates	$50	+69.72%	Jun 2, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

121.91M

from 54.03M

125.65%

from 54.03M

Revenue Next Year

256.79M

from 121.91M

110.63%

from 121.91M

EPS This Year

-6.18

from -7.12

EPS Next Year

-4.72

from -6.18

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	14.24M	26.82M	36.50M	54.03M	121.91M
Revenue Growth	-	-	88.36%	36.07%	48.03%	125.65%
Gross Profit	-256.97M	-267.37M	-271.58M	-268.95M	-291.85M	109.60M
Gross Margin	-	-1,877.63%	-1,012.50%	-736.90%	-540.19%	89.90%
Operating Income	-378.42M	-389.05M	-391.49M	-425.74M	-472.13M	-416.87M
Net Income	1.60B	-231.80M	-352.09M	673.73M	-412.78M	-369.50M
EPS	-	-	-	-	-7.12	-6.18
Free Cash Flow	-198.29M	-195.32M	-215.06M	-222.83M	-267.97M	-209.00M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	165.7M
Avg	121.9M
Low	88.8M

Revenue Growth

Revenue Growth	2026	2027	2028
High	206.6%
Avg	125.6%
Low	64.4%

EPS Forecast

EPS	2026	2027	2028
High	-5.50
Avg	-6.18
Low	-7.21

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-